Biocon Stock

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Stocks to watch on Thursday, January 22, 2026: KEI Industries, Bajaj Consumer Care, PNB Housing Finance and Jindal Stainless are among other key stocks to track today

The optimism stems from the company's plan to increase its stake in Biocon Biologics (BBL), the expected consolidation of the Biologics arm, and improving fundamentals

The board of directors of Biocon are scheduled to meet on December 06, 2025, to consider and approve the proposals for investment in Biocon Biologics, an unlisted material subsidiary of the company.

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

MOFSL and JM Financial retained their Buy ratings, while Nuvama upgraded Biocon to Buy from Hold after the company posted a net profit of ₹85 crore in Q2FY26

Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon, announced the expansion of its strategic collaboration with Civica, Inc. (Civica)

By 10:35 AM, Biocon share price was trading 2.84 per cent higher at ₹364.45 per share. In comparison, BSE Sensex was trading 0.38 per cent higher at 83,004.53 levels.

Biocon inaugurated its first US manufacturing facility in Cranbury through Biocon Generics, expanding its global footprint and strengthening supply chains for essential therapies

The inspection covered various aspects of operations including drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses

Biocon shares fell 3 per cent after it reported a 95.2 per cent decline in net profit in Q1FY26

The biopharma company's revenue from operations for the quarter ended June 30, 2025, surged 15 per cent year-on-year (Y-o-Y) to ₹3,942 crore, as compared to ₹3,433 crore reported in Q1FY25.

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

At 09:30 AM, Biocon shares were trading at ₹398.15, up by 1.97 per cent on the National Stock Exchange.

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Analyst at HDFC Securities have recommended a 'Bear Spread' Strategy on the Nifty MidCap index as it has broken out from the downward sloping trendline on the weekly charts

The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the treatment of type 2 diabetes.